A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor

Trial Profile

A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs MOR 208 (Primary) ; Idelalisib; Venetoclax
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms COSMOS
  • Sponsors MorphoSys
  • Most Recent Events

    • 23 Oct 2017 Primary endpoint has been changed from Overall response rate to Incidence and severity of adverse events (AEs) hence focus of the trial has been changed and planned patients number has also decreases.
    • 23 Oct 2017 Planned number of patients changed from 240 to 24.
    • 23 Oct 2017 Planned primary completion date changed from 1 Nov 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top